Changes in Beneficial Ownership · 4
Elutia Inc.
ELUTNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06222026_050601.xml
Filing details
- Report period
- 2026-06-21
- Issuer
- ELUTIA INC.
- Issuer CIK
- 0001708527
- Trading symbol
- ELUT
Reporting owner 1
- Name
- Mills C Randal
- Reporting owner CIK
- 0001370939
- Relationship
- Director · Officer
- Officer title
- PRESIDENT AND CEO
- Address
- C/O ELUTIA INC., 20 FIRSTFIELD ROAD, GAITHERSBURG, MD, 20878
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Class A Common Stock | 2026-06-21 | M · Form 4 | 22,473[F1] | A | [F2] | 449,244 | D |
| Class A Common Stock | 2026-06-21 | F · Form 4 | 8,064[F3] | D | 1.06 | 441,180 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock Units | [F2] | 2026-06-21 | M · Form 4 | 22,473 | D | 0 | [F4] | [F4] | Class A Common Stock | 22,473 | 0 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- Transaction represents shares of the Issuer's Class A Common Stock received from the vesting of restricted stock units.↩ 1
- F2
- Each restricted stock unit represents a contingent right to receive one share of Issuer Class A Common Stock.↩ 1↩ 2
- F3
- Shares withheld by the Issuer to satisfy tax withholding requirements on vesting of restricted stock units.↩ 1
Signature 1
- Signed
- /s/ Jeffrey Hamet, Attorney-in-Fact for C. Randal Mills
- Date
- 2026-06-22
Company context
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www. Elutia.com.